Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Sapna Patel

Concepts (168)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Melanoma
45
2026
764
7.840
Why?
Skin Neoplasms
21
2026
805
3.400
Why?
Ipilimumab
10
2026
44
2.670
Why?
Uveal Neoplasms
5
2024
16
2.170
Why?
Antineoplastic Combined Chemotherapy Protocols
12
2026
1996
1.410
Why?
Neoadjuvant Therapy
8
2026
474
1.330
Why?
Antineoplastic Agents, Immunological
5
2023
200
1.250
Why?
Antibodies, Monoclonal, Humanized
11
2026
992
1.130
Why?
Programmed Cell Death 1 Receptor
10
2026
268
1.060
Why?
B7-H1 Antigen
5
2024
245
0.930
Why?
Immunotherapy
6
2026
669
0.890
Why?
Neoplasms, Unknown Primary
1
2025
20
0.860
Why?
Biomarkers, Tumor
4
2026
1334
0.800
Why?
Lymphocytes, Tumor-Infiltrating
5
2026
155
0.730
Why?
CTLA-4 Antigen
6
2026
105
0.720
Why?
Vaccines, Subunit
1
2021
53
0.660
Why?
Receptor, IGF Type 1
1
2020
64
0.640
Why?
Toll-Like Receptors
1
2021
193
0.620
Why?
Dacarbazine
3
2017
98
0.560
Why?
Interleukin-2
4
2025
434
0.470
Why?
Neoplasm Staging
8
2024
1486
0.460
Why?
Neoplasm Metastasis
7
2026
693
0.400
Why?
Lymphocyte Depletion
2
2025
135
0.380
Why?
Drug Resistance, Neoplasm
4
2026
889
0.350
Why?
Choroid Neoplasms
1
2011
9
0.340
Why?
Middle Aged
26
2026
36359
0.340
Why?
Humans
48
2026
145625
0.330
Why?
Immunotherapy, Adoptive
3
2026
356
0.330
Why?
Aged
22
2026
26251
0.320
Why?
Adult
26
2026
40821
0.320
Why?
Antineoplastic Agents
4
2016
2218
0.310
Why?
Quality of Life
1
2023
3187
0.310
Why?
Male
29
2026
73014
0.300
Why?
Quinazolines
1
2011
267
0.300
Why?
Chemotherapy, Adjuvant
4
2025
429
0.300
Why?
Mucous Membrane
3
2025
129
0.300
Why?
Protein Kinase Inhibitors
2
2016
982
0.290
Why?
Combined Modality Therapy
6
2026
1269
0.270
Why?
Female
30
2026
79080
0.270
Why?
Aged, 80 and over
11
2025
8351
0.260
Why?
Antigen-Presenting Cells
1
2026
161
0.230
Why?
Interleukin-7
1
2026
66
0.230
Why?
Circulating Tumor DNA
1
2026
50
0.230
Why?
Carcinoma, Renal Cell
2
2019
229
0.220
Why?
Lymph Node Excision
1
2026
173
0.210
Why?
Indolizines
1
2024
13
0.210
Why?
Cyclic N-Oxides
1
2024
32
0.210
Why?
Pyridinium Compounds
1
2024
31
0.210
Why?
Adjuvants, Immunologic
2
2023
243
0.210
Why?
Imidazoles
3
2024
244
0.200
Why?
Gastrointestinal Microbiome
2
2021
767
0.190
Why?
Kidney Neoplasms
2
2019
417
0.190
Why?
Drug-Related Side Effects and Adverse Reactions
2
2023
266
0.190
Why?
Prognosis
7
2026
4331
0.190
Why?
Disease-Free Survival
5
2018
777
0.190
Why?
Neoplasms
4
2021
2944
0.180
Why?
Treatment Outcome
9
2025
11744
0.170
Why?
Dietary Fiber
1
2021
59
0.170
Why?
Urethral Neoplasms
1
2021
3
0.170
Why?
Vaginal Neoplasms
1
2021
20
0.170
Why?
Probiotics
1
2021
61
0.170
Why?
Oximes
2
2018
26
0.160
Why?
Proto-Oncogene Proteins B-raf
3
2018
230
0.160
Why?
Rare Diseases
1
2021
115
0.160
Why?
Pyrimidinones
2
2018
124
0.150
Why?
Salvage Therapy
1
2021
163
0.150
Why?
CD8-Positive T-Lymphocytes
1
2026
929
0.150
Why?
Cancer Vaccines
1
2021
161
0.150
Why?
Neoplasm Recurrence, Local
2
2023
1156
0.140
Why?
Autoimmune Diseases
1
2023
466
0.140
Why?
Pyridones
2
2018
210
0.140
Why?
Interleukin-9
1
2018
12
0.140
Why?
Carboplatin
1
2018
168
0.140
Why?
Antibodies, Monoclonal
3
2026
1511
0.130
Why?
Liver Neoplasms
1
2024
774
0.130
Why?
T-Lymphocytes
3
2021
2007
0.130
Why?
Dendritic Cells
1
2021
507
0.130
Why?
Disease Progression
2
2023
2857
0.130
Why?
Paclitaxel
1
2018
258
0.130
Why?
Mutation
4
2018
4082
0.120
Why?
Immunomodulation
1
2016
98
0.110
Why?
Chromosome Aberrations
1
2016
167
0.110
Why?
Texas
2
2018
279
0.110
Why?
DNA Mutational Analysis
1
2016
409
0.110
Why?
MAP Kinase Signaling System
1
2016
306
0.100
Why?
Survival Rate
3
2026
2078
0.100
Why?
Early Detection of Cancer
2
2016
501
0.100
Why?
Molecular Targeted Therapy
1
2016
446
0.100
Why?
Genetic Testing
1
2016
491
0.090
Why?
Research
1
2016
421
0.090
Why?
Young Adult
7
2021
14240
0.090
Why?
Risk Factors
2
2021
10840
0.070
Why?
Lung Neoplasms
1
2023
2674
0.070
Why?
Survival Analysis
3
2018
1372
0.070
Why?
Drug Therapy, Combination
2
2022
1034
0.070
Why?
Cell Line, Tumor
3
2024
3538
0.070
Why?
Confidence Intervals
2
2021
328
0.070
Why?
Recombinant Proteins
2
2026
1361
0.070
Why?
Administration, Oral
1
2011
867
0.070
Why?
ErbB Receptors
1
2011
636
0.070
Why?
Kaplan-Meier Estimate
2
2021
959
0.060
Why?
Genetic Predisposition to Disease
1
2016
2455
0.060
Why?
Time Factors
2
2021
7079
0.060
Why?
Cisplatin
2
2021
346
0.060
Why?
Neoplasm, Residual
1
2026
143
0.060
Why?
Lymphatic Metastasis
1
2026
335
0.050
Why?
Biomarkers
1
2016
4329
0.050
Why?
Follow-Up Studies
2
2026
5397
0.050
Why?
Immunologic Memory
1
2026
369
0.050
Why?
New York
1
2023
127
0.050
Why?
Oxidative Phosphorylation
1
2024
212
0.050
Why?
Biopsy
2
2017
1073
0.050
Why?
Cohort Studies
3
2021
6045
0.050
Why?
Bridged Bicyclo Compounds, Heterocyclic
1
2024
291
0.040
Why?
Immunohistochemistry
2
2016
1709
0.040
Why?
Retrospective Studies
3
2026
17291
0.040
Why?
Fecal Microbiota Transplantation
1
2021
27
0.040
Why?
MART-1 Antigen
1
2021
9
0.040
Why?
Fatty Acids, Volatile
1
2021
60
0.040
Why?
Xenograft Model Antitumor Assays
1
2024
928
0.040
Why?
Response Evaluation Criteria in Solid Tumors
1
2021
21
0.040
Why?
Melanoma, Experimental
1
2021
106
0.040
Why?
L-Lactate Dehydrogenase
1
2021
112
0.040
Why?
Mice
3
2024
18266
0.040
Why?
Hydrolases
1
2021
42
0.040
Why?
Mice, Inbred C57BL
2
2021
6021
0.040
Why?
Risk Assessment
2
2022
3678
0.040
Why?
Radiotherapy
1
2021
209
0.040
Why?
Receptors, Antigen, T-Cell
1
2023
676
0.040
Why?
Interleukin-1beta
1
2021
394
0.040
Why?
Feces
1
2021
494
0.030
Why?
Maximum Tolerated Dose
1
2018
216
0.030
Why?
Mohs Surgery
1
2018
30
0.030
Why?
Cancer Care Facilities
1
2018
48
0.030
Why?
Standard of Care
1
2018
81
0.030
Why?
Neoplasms, Second Primary
1
2018
103
0.030
Why?
Cell Proliferation
1
2024
2497
0.030
Why?
Ribosomal Protein S6
1
2016
18
0.030
Why?
Clone Cells
1
2017
259
0.030
Why?
Antineoplastic Agents, Alkylating
1
2016
76
0.030
Why?
Taxoids
1
2016
115
0.030
Why?
CD8 Antigens
1
2016
70
0.030
Why?
Gene Dosage
1
2017
146
0.030
Why?
Cell-Free System
1
2016
54
0.030
Why?
Neoplasm Invasiveness
1
2018
503
0.030
Why?
DNA Copy Number Variations
1
2017
189
0.030
Why?
Mitogen-Activated Protein Kinase 3
1
2016
133
0.030
Why?
Polyethylene Glycols
1
2021
649
0.030
Why?
Apoptosis
1
2024
2436
0.030
Why?
Animals
3
2024
38030
0.030
Why?
Mitogen-Activated Protein Kinase 1
1
2016
169
0.030
Why?
Mitogen-Activated Protein Kinases
1
2016
288
0.030
Why?
Cluster Analysis
1
2016
494
0.030
Why?
Genome
1
2017
307
0.030
Why?
Macrophages
1
2022
1530
0.030
Why?
Academic Medical Centers
1
2018
560
0.030
Why?
T-Lymphocyte Subsets
1
2016
415
0.030
Why?
Disease Models, Animal
1
2024
4565
0.020
Why?
Adaptor Proteins, Signal Transducing
1
2016
427
0.020
Why?
Interferon-alpha
1
2014
201
0.020
Why?
Surveys and Questionnaires
1
2026
6050
0.020
Why?
Phosphorylation
1
2016
1717
0.020
Why?
Sensitivity and Specificity
1
2016
1992
0.020
Why?
Adolescent
2
2021
22451
0.020
Why?
Dose-Response Relationship, Drug
1
2014
2018
0.020
Why?
Gene Expression Profiling
1
2016
1790
0.020
Why?
Prospective Studies
1
2016
8087
0.010
Why?
Signal Transduction
1
2016
5234
0.010
Why?
Patel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)